Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)
Multiple Myeloma
About this trial
This is an interventional treatment trial for Multiple Myeloma focused on measuring Iberdomide, CC-220, Daratumumab, Darzalex Faspro, Bortezomib, Velcade, Dexamethasone, MM, Multiple Myeloma, RRMM, CELMoD, Cereblon Modulators
Eligibility Criteria
Inclusion Criteria:
- Documented diagnosis of multiple myeloma (MM) and measurable disease
- Received 1 to 2 prior lines of anti-myeloma therapy
- Must have documented disease progression during or after their last anti-myeloma regimen
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2
Exclusion Criteria:
- Any condition that confounds the ability to interpret data from the study
- Has plasma cell leukemia, Waldenstrom's macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or clinically significant amyloidosis
- Known central nervous system involvement with MM
- Prior therapy with iberdomide
Other protocol-defined inclusion/exclusion criteria apply
Sites / Locations
- Genesis cancer and Blood Institute (GCBI) - Sarah CannonRecruiting
- Local Institution - 033Recruiting
- Local Institution - 029
- Advent Health
- Local Institution - 028
- Local Institution - 034
- Emory University
- Hematology-Oncology ClinicRecruiting
- Center For Cancer And Blood DisordersRecruiting
- Dana Farber Cancer Institute
- UMASS Memorial HospitalRecruiting
- HCA Midwest HealthRecruiting
- Local Institution - 015
- NYU Winthrop Hospital
- New York University School Of Medicine
- New York - Presbyterian/Weill Cornell Medical Center
- Duke University Hospital
- TriHealth, Good Samaritan HospitalRecruiting
- MetroHealth Medical Center - Main Campus
- Cleveland Clinic - Taussig Cancer Institute
- Ohio Health CorporationRecruiting
- Avera Cancer Institute
- Tennessee OncologyRecruiting
- Tennessee Oncology Nashville Drug Development UnitRecruiting
- UT Southwestern Simmons Cancer Center
- University Of WisconsinRecruiting
- Local Institution - 032
- Local Institution - 080
- Local Institution - 083
- Local Institution - 081
- Local Institution - 082
- Local Institution - 812
- Local Institution - 803Recruiting
- Local Institution - 806Recruiting
- Local Institution - 802Recruiting
- Local Institution - 809Recruiting
- Local Institution - 801Recruiting
- Local Institution - 811Recruiting
- Local Institution - 807Recruiting
- Local Institution - 804Recruiting
- Local Institution - 800Recruiting
- Local Institution - 808Recruiting
- Local Institution - 155Recruiting
- Local Institution - 152
- Local Institution - 154Recruiting
- Local Institution - 153Recruiting
- Local Institution - 156Recruiting
- Local Institution - 150Recruiting
- Local Institution - 151
- Local Institution - 157
- Local Institution - 172Recruiting
- Local Institution - 174Recruiting
- Local Institution - 170Recruiting
- Local Institution - 056
- Local Institution - 058
- Local Institution - 050
- Local Institution - 054
- Local Institution - 051
- Local Institution - 053
- Local Institution - 055
- Local Institution - 057
- Local Institution - 052
- Local Institution - 111Recruiting
- Local Institution - 103Recruiting
- Local Institution - 112Recruiting
- Local Institution - 104Recruiting
- Local Institution - 110Recruiting
- Local Institution - 101Recruiting
- Local Institution - 105
- Local Institution - 113
- Local Institution - 106
- Local Institution - 109
- Local Institution - 107
- Local Institution - 108Recruiting
- Local Institution - 129Recruiting
- Local Institution - 140Recruiting
- Local Institution - 139Recruiting
- Local Institution - 138Recruiting
- Local Institution - 126Recruiting
- Local Institution - 121Recruiting
- Local Institution - 135Recruiting
- Local Institution - 136Recruiting
- Local Institution - 128Recruiting
- Local Institution - 120Recruiting
- Local Institution - 127Recruiting
- Local Institution - 134Recruiting
- Local Institution - 132Recruiting
- Local Institution - 130
- Local Institution - 131Recruiting
- Local Institution - 124Recruiting
- Local Institution - 133Recruiting
- Local Institution - 137Recruiting
- Local Institution - 125Recruiting
- Local Institution - 123Recruiting
- Local Institution - 601Recruiting
- Local Institution - 600Recruiting
- Local Institution - 602Recruiting
- Local Institution - 371
- Local Institution - 370Recruiting
- Local Institution - 372Recruiting
- Local Institution - 230Recruiting
- Local Institution - 232Recruiting
- Local Institution - 231Recruiting
- Local Institution - 463Recruiting
- Local Institution - 462Recruiting
- Local Institution - 451Recruiting
- Local Institution - 455
- Local Institution - 458Recruiting
- Local Institution - 454
- Local Institution - 452Recruiting
- Local Institution - 456Recruiting
- Local Institution - 464Recruiting
- Local Institution - 450
- Local Institution - 465Recruiting
- Local Institution - 457Recruiting
- Local Institution - 0978
- Local Institution - 308
- Local Institution - 307
- Local Institution - 301
- Local Institution - 300Recruiting
- Local Institution - 302Recruiting
- Local Institution - 305Recruiting
- Local Institution - 304
- Local Institution - 303
- Local Institution - 571Recruiting
- Local Institution - 572Recruiting
- Local Institution - 570Recruiting
- Local Institution - 930
- Local Institution - 934
- Local Institution - 933
- Local Institution - 932
- Local Institution - 935
- Local Institution - 931
- Local Institution - 752
- Local Institution - 750Recruiting
- Local Institution - 753
- Local Institution - 751
- Local Institution - 872Recruiting
- Local Institution - 871Recruiting
- Local Institution - 870Recruiting
- Local Institution - 873Recruiting
- Local Institution - 415
- Local Institution - 400
- Local Institution - 408
- Local Institution - 414
- Local Institution - 404
- Local Institution - 407
- Local Institution - 410
- Local Institution - 411
- Local Institution - 412
- Local Institution - 402
- Local Institution - 405
- Local Institution - 413
- Local Institution - 401
- Local Institution - 403
- Local Institution - 409
- Local Institution - 406
- Local Institution - 900Recruiting
- Local Institution - 915
- Local Institution - 912Recruiting
- Local Institution - 916
- Local Institution - 911Recruiting
- Local Institution - 903Recruiting
- Local Institution - 902Recruiting
- Local Institution - 910Recruiting
- Local Institution - 901Recruiting
- Local Institution - 905Recruiting
- Local Institution - 908Recruiting
- Local Institution - 907Recruiting
- Local Institution - 913Recruiting
- Local Institution - 914Recruiting
- Local Institution - 906Recruiting
- Local Institution - 909Recruiting
- Local Institution - 904Recruiting
- Local Institution - 974Recruiting
- Local Institution - 973Recruiting
- Local Institution - 975Recruiting
- Local Institution - 971Recruiting
- Local Institution - 976Recruiting
- Local Institution - 972Recruiting
- Local Institution - 970Recruiting
- Local Institution - 977Recruiting
- Local Institution - 182
- Local Institution - 183
- Local Institution - 181
- Local Institution - 180
- Local Institution - 351Recruiting
- Local Institution - 354Recruiting
- Local Institution - 352Recruiting
- Local Institution - 202Recruiting
- Local Institution - 200Recruiting
- Local Institution - 201Recruiting
- Local Institution - 631Recruiting
- Local Institution - 633Recruiting
- Local Institution - 635Recruiting
- Local Institution - 634
- Local Institution - 636Recruiting
- Local Institution - 630Recruiting
- Local Institution - 632
- Local Institution - 545Recruiting
- Local Institution - 543Recruiting
- Local Institution - 544Recruiting
- Local Institution - 540Recruiting
- Local Institution - 541Recruiting
- Local Institution - 675
- Local Institution - 673
- Local Institution - 670
- Local Institution - 671
- Local Institution - 674
- Local Institution - 505Recruiting
- Local Institution - 502Recruiting
- Local Institution - 511Recruiting
- Local Institution - 501Recruiting
- Local Institution - 509Recruiting
- Local Institution - 510Recruiting
- Local Institution - 0979
- Local Institution - 516Recruiting
- Local Institution - 504Recruiting
- Local Institution - 513Recruiting
- Local Institution - 503Recruiting
- Local Institution - 508Recruiting
- Local Institution - 506Recruiting
- Local Institution - 514Recruiting
- Local Institution - 515Recruiting
- Local Institution - 500Recruiting
- Local Institution - 512Recruiting
- Local Institution - 507Recruiting
- Local Institution - 272Recruiting
- Local Institution - 274
- Local Institution - 271Recruiting
- Local Institution - 270
- Local Institution - 851Recruiting
- Local Institution - 850Recruiting
- Local Institution - 955Recruiting
- Local Institution - 952Recruiting
- Local Institution - 954Recruiting
- Local Institution - 951Recruiting
- Local Institution - 956Recruiting
- Local Institution - 950Recruiting
- Local Institution - 953Recruiting
- Local Institution - 776
- Local Institution - 771Recruiting
- Local Institution - 775
- Local Institution - 770Recruiting
- Local Institution - 772Recruiting
- Local Institution - 774Recruiting
- Local Institution - 773Recruiting
- Local Institution - 702
- Local Institution - 705
- Local Institution - 700
- Local Institution - 707Recruiting
- Local Institution - 704Recruiting
- Local Institution - 701Recruiting
- Local Institution - 709
- Local Institution - 706Recruiting
- Local Institution - 711
- Local Institution - 713
- Local Institution - 703
- Local Institution - 708Recruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Active Comparator
Daratumumab in combination with Iberdomide and dexamethasone - Dose 1
Daratumumab in combination with Iberdomide and dexamethasone - Dose 2
Daratumumab in combination with Iberdomide and dexamethasone - Dose 3
Daratumumab in combination with dexamethasone and bortezomib
Participants will receive oral iberdomide, subcutaneous daratumumab and oral dexamethasone.
Participants will receive subcutaneous daratumumab, bortezomib and oral dexamethasone